Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Boule Diagnostics ABCHIX:BOULS 47 Intrinsic Value: Projected FCF is kr-13.15 as of Aug. 16, 2026. GuruFocus rates CHIX:BOULS with a GF Score™ of 47/100 and a GF Value™ of kr48.59. The stock has 2 warning signs investors should review. Among 402 Medical Devices & Instruments companies, Boule Diagnostics AB ranks worse than 248755.97% on this metric.
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.
The historical rank and industry rank for Boule Diagnostics AB's Intrinsic Value: Projected FCF or its related term are showing as below:
During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Boule Diagnostics AB was 9.57. The lowest was 1.38. And the median was 3.42.
CHIX:BOULs's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.515 * Ranked among companies with meaningful Price-to-Projected-FCF only.
Boule Diagnostics AB (CHIX:BOULs) Intrinsic Value: Projected FCF Explanation
The growth multiple is capped between 8.35 and 17.74.
Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.
Boule Diagnostics AB's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as
Price-to-Intrinsic-Value-Projected-FCF
=
Share Price
/
Intrinsic Value: Projected FCF
=
26.30
/
-1.7387396247431
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB Intrinsic Value: Projected FCF Related Terms
Boule Diagnostics AB Intrinsic Value: Projected FCF Historical Data
* Premium members only.
The historical data trend for Boule Diagnostics AB's Intrinsic Value: Projected FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Boule Diagnostics AB Intrinsic Value: Projected FCF Chart
CHIX:BOULS vs ABT, SYK, MDT: Intrinsic Value: Projected FCF Comparison
For the Medical Devices subindustry, Boule Diagnostics AB's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Boule Diagnostics AB Price-to-Projected-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Boule Diagnostics AB's Price-to-Projected-FCF distribution charts can be found below:
* The bar in red indicates where Boule Diagnostics AB's Price-to-Projected-FCF falls into.
Boule Diagnostics AB Intrinsic Value: Projected FCF Calculation
Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.
The details of how we calculate the intrinsic value of stocks are described in detail here.
This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Intrinsic Value: Projected FCF of kr-13.15 mean?
Boule Diagnostics AB (CHIX:BOULS) has a Intrinsic Value: Projected FCF of kr-13.15 as of Aug. 16, 2026. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Boule Diagnostics AB and its competitors. Over the past decade, Boule Diagnostics AB's Intrinsic Value: Projected FCF has ranged from 1.38 to 9.57. According to the industry distribution chart, Boule Diagnostics AB ranks #999999 out of 402 companies in the Medical Devices & Instruments industry.
Is Boule Diagnostics AB's Intrinsic Value: Projected FCF too high?
Boule Diagnostics AB's current Intrinsic Value: Projected FCF is kr-13.15. Over the past 10 years, this metric has ranged from a low of 1.38 to a high of 9.57. Based on the distribution chart, Boule Diagnostics AB ranks #999999 out of 402 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Boule Diagnostics AB has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does Boule Diagnostics AB's Intrinsic Value: Projected FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Boule Diagnostics AB ranks #999999 out of 402 companies for Intrinsic Value: Projected FCF. This places Boule Diagnostics AB in the lower half of its industry. The industry median Intrinsic Value: Projected FCF is 1.52. Historically, Boule Diagnostics AB's own Intrinsic Value: Projected FCF has ranged from 1.38 to 9.57 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Intrinsic Value: Projected FCF for a Medical Devices & Instruments company?
The median Intrinsic Value: Projected FCF among Medical Devices & Instruments companies is 1.52, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a Intrinsic Value: Projected FCF significantly above this median, while those in the bottom quartile fall well below. However, Intrinsic Value: Projected FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Intrinsic Value: Projected FCF mean?
A high Intrinsic Value: Projected FCF can signal that a stock is expensive relative to its fundamentals. Intrinsic Value: Projected FCF is the stock value based on a projected free cash flow model. View historical data on Boule Diagnostics AB and its competitors. For the Medical Devices & Instruments industry, the median Intrinsic Value: Projected FCF is 1.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Boule Diagnostics AB's current Intrinsic Value: Projected FCF is kr-13.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Boule Diagnostics AB stock overvalued right now?
Boule Diagnostics AB (CHIX:BOULS) has a current Intrinsic Value: Projected FCF of kr-13.15. The stock's GF Value™ is kr48.59, compared to a current price of kr26.30 — trading 45.9% below its estimated fair value. The current Intrinsic Value: Projected FCF is kr-13.15. Boule Diagnostics AB's overall GF Score™ is 47/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Intrinsic Value: Projected FCF calculated?
Intrinsic Value: Projected FCF is calculated from a company's financial statements. For Boule Diagnostics AB (CHIX:BOULS), the current Intrinsic Value: Projected FCF is kr-13.15 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Boule Diagnostics AB (CHIX:BOULS) Overvalued in 2026?
Based on GuruFocus' analysis, Boule Diagnostics AB stock appears to be undervalued.
The current stock price of kr26.30 is trading 45.9% below its estimated GF Value™ of kr48.59.
Key valuation signals for CHIX:BOULS:
Intrinsic Value: Projected FCF: kr-13.15
GF Value™: kr48.59 vs. price of kr26.30 (45.9% below fair value)
No single metric tells the full story. See the CHIX:BOULS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Boule Diagnostics AB is a company operating in the diagnostics market. It is engaged in the development, manufacturing and marketing instruments and consumables for blood diagnostics. The systems are intended for small and medium-sized hospitals, clinics and laboratories within outpatient care. the company operating through two complementary business segments: Diagnostics and OEM CDS. Through its subsidiaries, the company operates in USA ,Asia, Eastern Europe, Latin America Western Europe and Africa / Middle East. The majority revenue is generated from Asia.
47GF Score
Get the complete analysis for CHIX:BOULS
Intrinsic Value: Projected FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:BOULS has been successfully added to your 
